Liqrev® (sildenafil) – New drug approval
April 28, 2023 - The FDA approved CMP Pharma’s Liqrev (sildenafil) oral suspension, for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening.
Download PDF
